IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A treatment protocol that enables patients to have continued access to IPI-926.
Basal Cell Carcinoma|Chondrosarcoma
DRUG: IPI-926
Incidence of adverse events (AEs) and serious adverse events (SAEs), and laboratory test results, Monitoring of AEs, including SAEs as well as review of laboratory sample test data to assess safety and tolerability of IPI-926, Up to 30 days after the last patient study visit
The extension protocol is a continuation of treatment with IPI-926, as administered to each individual patient during participation in their original IPI-926 protocol.

Patients who are completing their participation in the original IPI-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with IPI-926 in the extension protocol.